Compare · LQDA vs TVTX
LQDA vs TVTX
Side-by-side comparison of Liquidia Corporation (LQDA) and Travere Therapeutics Inc. (TVTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LQDA and TVTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LQDA is the larger of the two at $7.11B, about 1.3x TVTX ($5.27B).
- LQDA has been more active in the news (13 items in the past 4 weeks vs 3 for TVTX).
- TVTX has more recent analyst coverage (25 ratings vs 17 for LQDA).
- Company
- Liquidia Corporation
- Travere Therapeutics Inc.
- Price
- -
- -
- Market cap
- $7.11B
- $5.27B
- 1M return
- -
- +6.29%
- 1Y return
- -
- +251.86%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 13
- 3
- Recent ratings
- 17
- 25
Liquidia Corporation
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension; and LIQ865, a sustained-release formulation of bupivacaine for the treatment of local post-operative pain. The company also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Travere Therapeutics Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Latest LQDA
- Chief Human Resource Officer Krepp Sarah converted options into 3,179 shares and sold $562,361 worth of shares (7,864 units at $71.51) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 117,178 units (SEC Form 4)
- Chief Development Officer Khindri Sanjeev sold $84,740 worth of shares (1,185 units at $71.51) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 65,947 units (SEC Form 4)
- CFO and COO Kaseta Michael converted options into 12,879 shares and sold $1,460,965 worth of shares (20,430 units at $71.51) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 345,805 units (SEC Form 4)
- Chief Executive Officer Jeffs Roger sold $2,520,683 worth of shares (35,249 units at $71.51) as part of a pre-agreed trading plan and converted options into 28,167 shares, decreasing direct ownership by 0.62% to 1,130,426 units (SEC Form 4)
- Chief Business Officer Adair Jason converted options into 10,251 shares and sold $562,289 worth of shares (7,863 units at $71.51) as part of a pre-agreed trading plan, increasing direct ownership by 1% to 217,126 units (SEC Form 4)
- General Counsel Schundler Russell converted options into 10,168 shares and sold $1,053,926 worth of shares (14,738 units at $71.51) as part of a pre-agreed trading plan, decreasing direct ownership by 0.75% to 605,962 units (SEC Form 4)
- Chief Medical Officer Saggar Rajeev converted options into 8,018 shares and sold $709,816 worth of shares (9,926 units at $71.51) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 171,799 units (SEC Form 4)
- Chief Commercial Officer Moomaw Scott converted options into 7,466 shares and sold $682,142 worth of shares (9,539 units at $71.51) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 182,485 units (SEC Form 4)
- Chief Accounting Officer Boyle Dana converted options into 3,179 shares and sold $643,740 worth of shares (9,002 units at $71.51) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 169,519 units (SEC Form 4)
- Director Bloch Stephen M sold $6,051,170 worth of shares (75,000 units at $80.68) (SEC Form 4)
Latest TVTX
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Travere Therapeutics Inc. filed SEC Form 8-K: Leadership Update
- CHIEF MEDICAL OFFICER Inrig Jula gifted 468 shares, decreasing direct ownership by 0.41% to 112,770 units (SEC Form 4)
- SEC Form S-8 filed by Travere Therapeutics Inc.
- Director Coughlin Timothy exercised 10,000 shares at a strike of $26.52 and sold $500,747 worth of shares (10,000 units at $50.07) as part of a pre-agreed trading plan (SEC Form 4)
- Director Baynes Roy D. exercised 4,500 shares at a strike of $21.38 and sold $225,000 worth of shares (4,500 units at $50.00) as part of a pre-agreed trading plan (SEC Form 4)
- Travere Therapeutics Inc. filed SEC Form 8-K: Leadership Update
- Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027
- SEC Form 144 filed by Travere Therapeutics Inc.
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)